News

MUSC And Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases

The Medical University of South Carolina (MUSC) and Bristol-Myers Squibb Company have announced their joint entry into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis (IPF). Under the agreement, studies designed to improve the mechanistic understanding of fibrosis, explore patient…

Updated International Guidelines Recommend OFEV (Nintedanib) for IPF Treatment

Boehringer Ingelheim recently announced that it welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline, as it suggests the use of OFEV (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF). This recommendation directed to clinicians is considered…

Study Provides New Insights Into Lung Repair Mechanisms After Damage, Fibrosis

The lung is constantly subjected to harmful exposures, such as inhaled toxic substances, particulate matter, autoimmune reactions, and viral or bacterial infections that cause injury to the airway and alveolar epithelium cells. In regenerative processes, these injured cells must be replaced as soon as possible. In a recent study published…